Literature DB >> 17139262

Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas.

Karoline Stur1, Franz M Karlhofer, Georg Stingl.   

Abstract

The clinical spectrum of cutaneous eruptions comprises benign variants like maculopapular rashes (MPRs) and potentially life-threatening events such as toxic epidermal necrolysis (TEN). Apoptosis of keratinocytes is a common histopathological feature of all these drug eruptions. As in skin lesions of TEN and Stevens-Johnson syndrome patients, apoptosis of keratinocytes is often accompanied by an only sparse cellular infiltrate, a soluble fatty acid synthetase ligand (sFASL)-mediated mechanism of keratinocyte cell death is postulated. In MPR patients, evidence for the occurrence of a similar process could not be established so far. We therefore examined sera and lesional skin sections from patients with clinical variants of drug eruptions for FASL expression using a sandwich ELISA and immunohistochemistry, respectively. As controls, healthy persons and patients with other inflammatory skin diseases such as viral exanthema were analyzed. Elevated levels of FASL were detected not only in TEN patients but also in sera and lesional skin of patients with MPR. In contrast, sFASL was repeatedly negative in all viral exanthemas and healthy controls tested. Thus, determination of sFASL serum concentration may represent a discriminating tool between drug rashes and viral exanthemas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17139262     DOI: 10.1038/sj.jid.5700648

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening.

Authors:  Suran L Fernando; Andrew J Broadfoot
Journal:  CMAJ       Date:  2009-11-23       Impact factor: 8.262

Review 2.  Drug-Induced vs. Viral Maculopapular Exanthem-Resolving the Dilemma.

Authors:  Sujay Khandpur; Rhea Ahuja
Journal:  Dermatopathology (Basel)       Date:  2022-05-07

Review 3.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

Review 4.  Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Akito Hasegawa; Riichiro Abe
Journal:  F1000Res       Date:  2020-06-16

5.  The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge.

Authors:  Jean-Christoph Caubet; Laurent Kaiser; Barbara Lemaître; Benoît Fellay; Alain Gervaix; Philippe A Eigenmann
Journal:  J Allergy Clin Immunol       Date:  2010-10-28       Impact factor: 10.793

6.  The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

Authors:  Michael Sadek; Omer Iqbal; Fakiha Siddiqui; Sean Till; Melissa Mazariegos; Edward Campbell; Kumaran Mudaliar; Jodi Speiser; Emily Bontekoe; Ahmed Kouta; Ambar Farooqui; Bharathi Daravath; Dalia Qneibi; Ramy Sadek; Debra Hoppensteadt; Jawed Fareed; Charles Bouchard
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

Review 7.  Current Perspectives on Severe Drug Eruption.

Authors:  Jingzhan Zhang; Zixian Lei; Chen Xu; Juan Zhao; Xiaojing Kang
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-17       Impact factor: 8.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.